Showing 2941-2950 of 7670 results for "".
- Industry Responds to COVID-19: NoSweathttps://practicaldermatology.com/news/industry-responds-to-covid-19-nosweat/2460695/Recognizing that any physical activity coupled with wearing a face shield can produce sweat that can get in the eyes and fog-up shields, NoSweat has created the first disposable performance liners specifically for face shields that absorb sweat while preventing fogging, odors, stains, and even acne…
- Dermavant: Promising Interim Analysis from Third Phase 3 Trial for Tapinarof in Psoriasishttps://practicaldermatology.com/news/dermavant-promising-interim-analysis-from-third-phase-3-trial-for-tapinarof-in-psoriasis/2460693/Positive results from a planned interim analysis of PSOARING 3, Dermavant Sciences’ long-term, open-label safety study, show that approximately 40 percent of subjects treated with investigational tapinarof cream, 1% achieved complete disease clearance (PGA score = 0). Treatment was well tolerated a…
- Klisyri Launches for Treatment of AKshttps://practicaldermatology.com/news/klisyri-launches-for-treatment-of-aks/2460691/Klisyri® (tirbanibulin) ointment 1% is now available from Almirall, SA for the topical treatment of actinic keratosis (AK) of the face and scalp. Klisyri is supplied in boxes of 5 single-use sachets and is applied to the treatment area once daily for five days. "Klisyri will help address unmet nee…
- Almirall’s Klisyri Performs Well in Phase III AK Trialshttps://practicaldermatology.com/news/almiralls-klisyri-performs-well-in-phase-iii-ak-trials/2460687/Almirall’s Klisyri (tirbanibulin) ointment demonstrated complete clearance of actinic keratosis (AK) lesions at day 57 in treated face or scalp areas in a significantly higher number of patients than vehicle, according to Phase III trials. What’s more, Klisyri is safe with no patient withdrawals f…
- DermTech Adds to Scientific Advisory Boardhttps://practicaldermatology.com/news/dermtech-adds-to-scientific-advisory-board/2460686/Drs. Lisa Beck and George Han are the newest members of DermTech’s Scientific Advisory Board, Lisa Beck, MD, is the co-director of the University of Rochester Medical Center for Allergic Disease Research and has served on the board of directors of the International Eczema Council since 2014. Speci…
- Ortho Dermatologics Opens Applications for 2021 Aspire Higher Scholarship Programhttps://practicaldermatology.com/news/ortho-dermatologics-opens-applications-for-2021-aspire-higher-scholarship-program/2460683/Ortho Dermatologics opened the application process for its 2021 Aspire Higher scholarship program. The program, which began in 2013, will award nine students who have been treated for a dermatologic condition with a scholarship of up to $10,000 in support of their academic goals. “Many students to…
- FDA Clears CellFX from Pulse Bioscienceshttps://practicaldermatology.com/news/fda-clears-cellfx-from-pulse-biosciences/2460682/The FDA has cleared the CellFX® System from Pulse Biosciences, Inc. for dermatologic procedures requiring ablation and resurfacing of the skin, and a controlled commercial launch will soon begin in the US with a select group of leaders in aesthetic dermatology. The CellFX System is a multi-applica…
- Soliton's RAP Technology Now Cleared for Cellulitehttps://practicaldermatology.com/news/solitons-rap-technology-now-cleared-for-cellulite/2460681/The FDA has cleared Soliton Inc.’s Rapid Acoustic Pulse (RAP) technology for the short-term improvement in the appearance of cellulite. Harnessing the power of sound, the unique, rapid-pulsed technology safely and comfortably breaks apart the fibrous septa bands beneath the skin that cause cellulit…
- Second-Draw PPP Loans: What Dermatologists Should Knowhttps://practicaldermatology.com/news/second-draw-ppp-loans-what-dermatologists-should-know/2460680/By Mark Schmidt, CEO, Fund-Ex Solutions Group Dermatologists have proven their resiliency throughout the pandemic, and now more help is here with another round of funding through the Paycheck Protection Program (PPP). The Economic Aid Act reopened the Small Business Administration’s PPP, and appli…
- New NEA Survey Puts Dollar Amounts on Cost of Living with ADhttps://practicaldermatology.com/news/new-nea-survey-puts-numbers-on-cost-of-living-with-ad/2460679/Fully 42 percent of Americans living with atopic dermatitis (AD) spend $1,000 or more out of pocket (OOP) every year to manage their eczema, accrdong to a new survey from the National Eczema Association (NEA). While the median annual estimated OOP expense is $600 across all survey respondents, an…